Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment

Ilaria Iacobucci, Gianantonio Rosti, Marilina Amabile, Angela Poerio, Simona Soverini, Daniela Cilloni, Nicoletta Testoni, Elisabetta Abruzzese, Enrico Montefusco, Emanuela Ottaviani, Francesco Iuliano, Domenico Russo, Marco Gobbi, Giuliana Alimena, Bruno Martino, Carolina Terragna, Fabrizio Pane, Giuseppe Saglio, Michele Baccarani, Giovanni Martinelli

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Purpose: Imatinib mesylate is a potent inhibitor of BCR-ABL, the constitutively active tyrosine kinase protein critical for the pathogenesis of chronic myeloid leukemia. Patients and Methods: We reviewed 284 patients with late chronic-phase Philadelphia chromosome (Ph) -positive chronic myeloid leukemia treated with imatinib 400 mg daily after interferon-α failure. In a retrospective study, we evaluated the pattern and rapidity of the response to imatinib, comparing the cytogenetic and molecular responses, progression-free and overall survival rates in patients who obtained a complete cytogenetic response within 1 year of treatment (early responders), and in patients where a complete cytogenetic response was detected after 12 months (late responders). Results: After 3 or 4 years of treatment, the molecular response of the late cytogenetic responders was similar to that of the early cytogenetic responders. At 36 months of treatment the amount of residual disease measured by standardized quantitative reverse-transcriptase polymerase chain reaction was 0.00047 in late responders versus 0.00022 in early responders, and at 48 months it was 0.00019 versus 0.00026 (median values, P value = nonsignificant). The estimated 4-year progression-free survival rate was 88% for early responders and 100% for late responders, while the estimated 4-year overall survival rates were 92% and 100% for early and late responders, respectively. Conclusion: The sensitivity and the response (cytogenic and molecular) to imatinib may require 1 year or more. Long-term follow-up results continue to improve in terms of rates and durability of the complete cytogenetic response, major or complete molecular response, and progession-free and overall survival.

Original languageEnglish
Pages (from-to)454-459
Number of pages6
JournalJournal of Clinical Oncology
Volume24
Issue number3
DOIs
Publication statusPublished - Jan 20 2006

Fingerprint

Leukemia, Myeloid, Chronic Phase
Cytogenetics
Survival Rate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Disease-Free Survival
Therapeutics
Philadelphia Chromosome
Reverse Transcriptase Polymerase Chain Reaction
Protein-Tyrosine Kinases
Interferons
Imatinib Mesylate
Retrospective Studies
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. / Iacobucci, Ilaria; Rosti, Gianantonio; Amabile, Marilina; Poerio, Angela; Soverini, Simona; Cilloni, Daniela; Testoni, Nicoletta; Abruzzese, Elisabetta; Montefusco, Enrico; Ottaviani, Emanuela; Iuliano, Francesco; Russo, Domenico; Gobbi, Marco; Alimena, Giuliana; Martino, Bruno; Terragna, Carolina; Pane, Fabrizio; Saglio, Giuseppe; Baccarani, Michele; Martinelli, Giovanni.

In: Journal of Clinical Oncology, Vol. 24, No. 3, 20.01.2006, p. 454-459.

Research output: Contribution to journalArticle

Iacobucci, I, Rosti, G, Amabile, M, Poerio, A, Soverini, S, Cilloni, D, Testoni, N, Abruzzese, E, Montefusco, E, Ottaviani, E, Iuliano, F, Russo, D, Gobbi, M, Alimena, G, Martino, B, Terragna, C, Pane, F, Saglio, G, Baccarani, M & Martinelli, G 2006, 'Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment', Journal of Clinical Oncology, vol. 24, no. 3, pp. 454-459. https://doi.org/10.1200/JCO.2005.03.2011
Iacobucci, Ilaria ; Rosti, Gianantonio ; Amabile, Marilina ; Poerio, Angela ; Soverini, Simona ; Cilloni, Daniela ; Testoni, Nicoletta ; Abruzzese, Elisabetta ; Montefusco, Enrico ; Ottaviani, Emanuela ; Iuliano, Francesco ; Russo, Domenico ; Gobbi, Marco ; Alimena, Giuliana ; Martino, Bruno ; Terragna, Carolina ; Pane, Fabrizio ; Saglio, Giuseppe ; Baccarani, Michele ; Martinelli, Giovanni. / Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 3. pp. 454-459.
@article{e8dc998e1f7542ba8ca6f17d9b133ca5,
title = "Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment",
abstract = "Purpose: Imatinib mesylate is a potent inhibitor of BCR-ABL, the constitutively active tyrosine kinase protein critical for the pathogenesis of chronic myeloid leukemia. Patients and Methods: We reviewed 284 patients with late chronic-phase Philadelphia chromosome (Ph) -positive chronic myeloid leukemia treated with imatinib 400 mg daily after interferon-α failure. In a retrospective study, we evaluated the pattern and rapidity of the response to imatinib, comparing the cytogenetic and molecular responses, progression-free and overall survival rates in patients who obtained a complete cytogenetic response within 1 year of treatment (early responders), and in patients where a complete cytogenetic response was detected after 12 months (late responders). Results: After 3 or 4 years of treatment, the molecular response of the late cytogenetic responders was similar to that of the early cytogenetic responders. At 36 months of treatment the amount of residual disease measured by standardized quantitative reverse-transcriptase polymerase chain reaction was 0.00047 in late responders versus 0.00022 in early responders, and at 48 months it was 0.00019 versus 0.00026 (median values, P value = nonsignificant). The estimated 4-year progression-free survival rate was 88{\%} for early responders and 100{\%} for late responders, while the estimated 4-year overall survival rates were 92{\%} and 100{\%} for early and late responders, respectively. Conclusion: The sensitivity and the response (cytogenic and molecular) to imatinib may require 1 year or more. Long-term follow-up results continue to improve in terms of rates and durability of the complete cytogenetic response, major or complete molecular response, and progession-free and overall survival.",
author = "Ilaria Iacobucci and Gianantonio Rosti and Marilina Amabile and Angela Poerio and Simona Soverini and Daniela Cilloni and Nicoletta Testoni and Elisabetta Abruzzese and Enrico Montefusco and Emanuela Ottaviani and Francesco Iuliano and Domenico Russo and Marco Gobbi and Giuliana Alimena and Bruno Martino and Carolina Terragna and Fabrizio Pane and Giuseppe Saglio and Michele Baccarani and Giovanni Martinelli",
year = "2006",
month = "1",
day = "20",
doi = "10.1200/JCO.2005.03.2011",
language = "English",
volume = "24",
pages = "454--459",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment

AU - Iacobucci, Ilaria

AU - Rosti, Gianantonio

AU - Amabile, Marilina

AU - Poerio, Angela

AU - Soverini, Simona

AU - Cilloni, Daniela

AU - Testoni, Nicoletta

AU - Abruzzese, Elisabetta

AU - Montefusco, Enrico

AU - Ottaviani, Emanuela

AU - Iuliano, Francesco

AU - Russo, Domenico

AU - Gobbi, Marco

AU - Alimena, Giuliana

AU - Martino, Bruno

AU - Terragna, Carolina

AU - Pane, Fabrizio

AU - Saglio, Giuseppe

AU - Baccarani, Michele

AU - Martinelli, Giovanni

PY - 2006/1/20

Y1 - 2006/1/20

N2 - Purpose: Imatinib mesylate is a potent inhibitor of BCR-ABL, the constitutively active tyrosine kinase protein critical for the pathogenesis of chronic myeloid leukemia. Patients and Methods: We reviewed 284 patients with late chronic-phase Philadelphia chromosome (Ph) -positive chronic myeloid leukemia treated with imatinib 400 mg daily after interferon-α failure. In a retrospective study, we evaluated the pattern and rapidity of the response to imatinib, comparing the cytogenetic and molecular responses, progression-free and overall survival rates in patients who obtained a complete cytogenetic response within 1 year of treatment (early responders), and in patients where a complete cytogenetic response was detected after 12 months (late responders). Results: After 3 or 4 years of treatment, the molecular response of the late cytogenetic responders was similar to that of the early cytogenetic responders. At 36 months of treatment the amount of residual disease measured by standardized quantitative reverse-transcriptase polymerase chain reaction was 0.00047 in late responders versus 0.00022 in early responders, and at 48 months it was 0.00019 versus 0.00026 (median values, P value = nonsignificant). The estimated 4-year progression-free survival rate was 88% for early responders and 100% for late responders, while the estimated 4-year overall survival rates were 92% and 100% for early and late responders, respectively. Conclusion: The sensitivity and the response (cytogenic and molecular) to imatinib may require 1 year or more. Long-term follow-up results continue to improve in terms of rates and durability of the complete cytogenetic response, major or complete molecular response, and progession-free and overall survival.

AB - Purpose: Imatinib mesylate is a potent inhibitor of BCR-ABL, the constitutively active tyrosine kinase protein critical for the pathogenesis of chronic myeloid leukemia. Patients and Methods: We reviewed 284 patients with late chronic-phase Philadelphia chromosome (Ph) -positive chronic myeloid leukemia treated with imatinib 400 mg daily after interferon-α failure. In a retrospective study, we evaluated the pattern and rapidity of the response to imatinib, comparing the cytogenetic and molecular responses, progression-free and overall survival rates in patients who obtained a complete cytogenetic response within 1 year of treatment (early responders), and in patients where a complete cytogenetic response was detected after 12 months (late responders). Results: After 3 or 4 years of treatment, the molecular response of the late cytogenetic responders was similar to that of the early cytogenetic responders. At 36 months of treatment the amount of residual disease measured by standardized quantitative reverse-transcriptase polymerase chain reaction was 0.00047 in late responders versus 0.00022 in early responders, and at 48 months it was 0.00019 versus 0.00026 (median values, P value = nonsignificant). The estimated 4-year progression-free survival rate was 88% for early responders and 100% for late responders, while the estimated 4-year overall survival rates were 92% and 100% for early and late responders, respectively. Conclusion: The sensitivity and the response (cytogenic and molecular) to imatinib may require 1 year or more. Long-term follow-up results continue to improve in terms of rates and durability of the complete cytogenetic response, major or complete molecular response, and progession-free and overall survival.

UR - http://www.scopus.com/inward/record.url?scp=33644838303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644838303&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.03.2011

DO - 10.1200/JCO.2005.03.2011

M3 - Article

VL - 24

SP - 454

EP - 459

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -